Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Return on Capital Employed (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Return on Capital Employed for 6 consecutive years, with 0.41% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Capital Employed fell 14.0% year-over-year to 0.41%, compared with a TTM value of 0.41% through Jun 2025, down 14.0%, and an annual FY2025 reading of 0.48%, down 10.0% over the prior year.
  • Return on Capital Employed was 0.41% for Q2 2025 at Avidity Biosciences, down from 0.3% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.2% in Q1 2021 and bottomed at 0.45% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.34%, with a median of 0.35% recorded in 2024.
  • The sharpest move saw Return on Capital Employed decreased -18bps in 2021, then grew 10bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.3% in 2021, then fell by -25bps to 0.37% in 2022, then decreased by -22bps to 0.45% in 2023, then skyrocketed by 41bps to 0.27% in 2024, then crashed by -52bps to 0.41% in 2025.
  • Business Quant data shows Return on Capital Employed for RNA at 0.41% in Q2 2025, 0.3% in Q1 2025, and 0.27% in Q2 2024.